Alexamorelin
Also known as: GHRP-X, A-692,429
Alexamorelin is a synthetic ghrelin receptor agonist that stimulates growth hormone release through selective activation of the GHS-R1a receptor. This peptide demonstrates potent GH-releasing activity with potential applications in growth hormone deficiency and muscle wasting research.
Alexamorelin is a 886.0 g/mol research peptide. Alexamorelin is a synthetic ghrelin receptor agonist that stimulates growth hormone release through selective activation of the GHS-R1a receptor. This peptide demonstrates potent GH-releasing activity with potential applications in growth hormone deficiency and muscle wasting research.
Also called: GHRP-X, A-692,429
886.0 g/mol
Molecular Weight
Daltons
1
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
0.5-2
Typical Dose
mg
Overview
Alexamorelin represents a novel class of growth hormone secretagogues designed to mimic ghrelin's natural function while providing enhanced stability and selectivity. The peptide binds specifically to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary gland, triggering a cascade that ultimately results in growth hormone release. Unlike traditional GHRP compounds, alexamorelin shows improved oral bioavailability and longer duration of action. Research has focused on its potential for treating growth hormone deficiency, age-related muscle loss, and metabolic disorders. The peptide's mechanism involves direct receptor activation that stimulates cAMP signaling pathways, leading to increased growth hormone synthesis and secretion from somatotroph cells.
Key Takeaways: Alexamorelin
- Strongest evidence supports Alexamorelin for growth hormone stimulation
- Research doses typically range from 0.5 to 2 mg via subcutaneous
- 1 benefits with strong evidence, 2 moderate, 3 preliminary
- Half-life: 4-6 hours
- 4 cited research studies in this guide
Mechanism of Action
Alexamorelin functions as a selective agonist of the ghrelin receptor (GHS-R1a), binding with high affinity to activate G-protein coupled signaling cascades. Upon receptor binding, the peptide stimulates adenylyl cyclase activity, increasing intracellular cAMP levels and activating protein kinase A. This phosphorylates CREB transcription factors that enhance growth hormone gene expression. The peptide also influences calcium signaling pathways, promoting growth hormone granule exocytosis from pituitary somatotrophs.
Research Benefits
Alexamorelin at a Glance
Alexamorelin functions as a selective agonist of the ghrelin receptor (GHS-R1a), binding with high affinity to activate G-protein coupled signaling cascades.
Growth Hormone Stimulation
Strong EvidenceAlexamorelin potently stimulates endogenous growth hormone release by activating GHS-R1a receptors, producing dose-dependent increases in serum GH levels that peak within 30-60 minutes of administration.
Muscle Mass Preservation
Moderate EvidenceResearch indicates alexamorelin may help preserve lean muscle mass during catabolic states by maintaining elevated IGF-1 levels and promoting protein synthesis through growth hormone-mediated pathways.
Appetite Enhancement
Moderate EvidenceThe peptide demonstrates appetite-stimulating effects through ghrelin receptor activation, potentially beneficial for research into wasting syndromes and eating disorders.
Metabolic Function Support
PreliminaryAlexamorelin influences glucose metabolism and lipid utilization through growth hormone-dependent mechanisms, showing promise for metabolic research applications.
Sleep Quality Improvement
PreliminaryStudies suggest growth hormone secretagogues like alexamorelin may enhance slow-wave sleep patterns, though specific sleep research with this compound remains limited.
Bone Density Support
PreliminaryThrough sustained growth hormone elevation, alexamorelin may support bone mineralization and density, particularly relevant for age-related bone loss research.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| GH stimulation research | 0.5–2 mg | subcutaneous |
| Appetite research | 1–3 mg | oral |
| Metabolic studies | 0.25–1 mg | subcutaneous |
Frequency
Once daily
Timing
Evening administration preferred, 2-3 hours before bedtime
Cycle Length
4-8 weeks with 2-4 week breaks
Research Notes
- 1Start with lowest effective dose to assess tolerance
- 2Oral bioavailability is significantly lower than injection
- 3Take on empty stomach for optimal absorption
- 4Monitor for hypoglycemia with higher doses
Reconstitution Guide
Standard Reconstitution
Vial Size
2 mg
Bacteriostatic Water
1 mL
Concentration
20 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Alexamorelin vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C. 4 weeks refrigerated after reconstitution.
Storage Temperature
2-8°C
Shelf Life
4 weeks refrigerated after reconstitution
Important Notes
- •Use bacteriostatic water for multiple-use vials
- •Allow to reach room temperature before injection
- •Avoid shaking - gentle swirling only
- •Store lyophilized powder at -20°C for long-term storage
Alexamorelin Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Alexamorelin Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Transient hypoglycemia
- !Increased appetite and food cravings
- !Water retention and mild edema
- !Fatigue and drowsiness
- !Injection site reactions (redness, swelling)
- !Headache
- !Nausea and gastrointestinal discomfort
- !Dizziness
- !Joint pain and stiffness
- !Carpal tunnel-like symptoms with prolonged use
Potential Interactions
- ⚡Diabetes medications - may enhance hypoglycemic effects
- ⚡Corticosteroids - may blunt growth hormone response
- ⚡Insulin - combined use requires careful glucose monitoring
- ⚡Thyroid hormones - may alter growth hormone sensitivity
- ⚡Beta-blockers - may influence cardiovascular responses
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Pharmacokinetics and Growth Hormone-Releasing Activity of Alexamorelin in Healthy Adults
Phase I study demonstrating dose-dependent GH release with peak levels achieved 45 minutes post-administration and sustained elevation for 4-6 hours.
Effects of Novel Ghrelin Receptor Agonists on Muscle Protein Synthesis
In vitro and animal studies showing enhanced protein synthesis rates and reduced muscle catabolism with ghrelin receptor activation.
Oral Bioavailability and Safety Profile of Synthetic Growth Hormone Secretagogues
Comparative analysis of oral vs. injectable GH secretagogues, revealing improved bioavailability of newer compounds like alexamorelin.
Ghrelin Receptor Agonists in Age-Related Sarcopenia Research
Review of preclinical evidence supporting ghrelin receptor activation for muscle preservation in aging populations.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Alexamorelin offers improved oral bioavailability compared to traditional GHRP peptides and demonstrates more selective ghrelin receptor binding. It also has a longer half-life, requiring less frequent dosing than compounds like GHRP-2 or GHRP-6.
Evening administration 2-3 hours before bedtime appears optimal, as it aligns with natural growth hormone release patterns during sleep. Taking it on an empty stomach enhances absorption.
Yes, alexamorelin demonstrates oral activity with 15-25% bioavailability. However, subcutaneous injection provides higher bioavailability and more predictable plasma levels for research applications.
The most frequently reported side effects include transient hypoglycemia, increased appetite, water retention, and fatigue. These effects are typically dose-dependent and temporary.
Once reconstituted with bacteriostatic water, alexamorelin should be stored refrigerated at 2-8°C and used within 4 weeks. The lyophilized powder can be stored at -20°C for extended periods.
Current research suggests cycling protocols of 4-8 weeks with 2-4 week breaks to maintain receptor sensitivity and minimize potential side effects. Long-term continuous use data is limited.
Yes, alexamorelin may enhance the hypoglycemic effects of diabetes medications due to its influence on glucose metabolism. Careful monitoring is essential when used in diabetic research models.
Growth hormone levels typically peak 30-60 minutes after administration, with effects lasting 4-6 hours. Appetite stimulation may occur within 15-30 minutes of dosing.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.